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Abstract
Zinc (Zn 2+ ), a multifunctional micronutrient, was recently shown to lower the affinity of cell-associated insulin-like growth factor (IGF) binding protein (IGFBP)-3 and IGFBP-5 for both IGF-I and IGF-II, but to increase the affinity of the cell surface type 1 IGF receptor (IGF-1R) for the same two ligands. However, there is a need for data concerning the effects of Zn 2+ on soluble IGFBPs and the type 2 IGF receptor (IGF-2R). In the current work, we demonstrate that Zn 2+ affects the affinity of IGFBP-5 secreted by myoblasts but not IGFBP-4. Zn 
Introduction
Myoblasts and satellite cells represent the precursor cells necessary for development and growth respectively of skeletal muscle. Both muscle development and growth are dependent on insulin-like growth factor (IGF) stimulation of myoblast proliferation, survival and differentiation into the functional multinucleated myofiber found in skeletal muscle (Novakofski & McCusker 2001) . Proliferation, survival, differentiation and hypertropy of skeletal myoblasts and myofibers are enhanced by IGF-I and IGF-II (Florini et al. 1996 , Adams 2002 , Frost & Lang 2003 . Clearly, factors that depress IGF activity markedly affect myoblast function, ex. cytokine-induced depression in type 1 IGF receptor (IGF-1R) signaling via intracellular receptor cross-talk alter protein synthesis and differentiation (Frost et al. 1997 , Broussard et al. 2003 . In addition to intracellular regulation, the presence of IGF binding proteins (IGFBPs) in extracellular fluids markedly affects IGF activity. Soluble IGFBPs decrease IGF binding to the IGF-1R. IGFBPs can also increase IGF activity by associating with the cell surface (Jones & Clemmons 1995) .
Thus the IGFBPs are important modulators of metabolism because of their ability to bind the IGFs with high affinity. IGFBPs -1, -2, -3, -5 and -6 have been shown to increase or depress IGF activity. In contrast, only in vitro inhibitory activity has been demonstrated for IGFBP-4. Inhibitory activity depends on the amount and affinity of the IGFBP (McCusker et al. 1991) .
Cultured skeletal myoblasts do not appear to have abundant cell-associated IGFBPs, but secrete either a single IGFBP or a wide variety of combinations of soluble IGFBPs including IGFBP-2, -3, -4, -5, -6 and -7 (rp1) (McCusker et al. 1989b , Ernst et al. 1992 , James et al. 1993 , McFarland et al. 1993 , Kou et al. 1994 , McCusker & Clemmons 1994 , 1998 , Bach et al. 1995 , Ernst & White 1996 , Hembree et al. 1996 , Damon et al. 1997 , Ewton et al. 1998 , Musaro & Rosenthal 1999 , Yang et al. 1999 , Bayol et al. 2000 , Crown et al. 2000 , Haugk et al. 2000 , Meadows et al. 2000 , Foulstone et al. 2001 , Rousse et al. 2001 , Yi et al. 2001 . With such an array of IGFBP profiles, it is difficult to interpret the specific role of a given IGFBP to myoblast function although clearly IGFBPs can act as autocrine and paracrine growth and differentiation modulators (McCusker & Clemmons 1988 , Hodgkinson et al. 1989 , Tollefsen et al. 1989 , Bach et al. 1994 , Ewton & Florini 1995 , Rotwein et al. 1995 , Silverman et al. 1995 , Ernst et al. 1996 , Ernst & White 1996 , James et al. 1996 , Stewart et al. 1996 , Damon et al. 1998a ,b, Fligger et al. 1998 , Rousse et al. 1998 , Meadows et al. 2000 , Foulstone et al. 2001 , Pampusch et al. 2003 . To understand fully the role of IGFBPs in myoblast function it is necessary to define factors that control IGFBP secretion, as determined in many of the references listed above, and also to determine factors that control IGFBP activity. It is important to remember that purified IGFBPs do not necessarily represent the IGFBP being secreted by a cell. This is simply illustrated by the fact that IGFBP-5 produced by glioblastoma cells tightly adheres to the cell surface (McCusker et al. 1990 , McCusker & Clemmons 1997 but the IGFBP-5 secreted by muscle cells is only found in the culture media and not on the cell surface (McCusker & Clemmons 1988 , McCusker et al. 1989a . Similarly, the IGFBP-3 produced by human fibroblasts tightly adheres to the cell surface and is resistant to washing, cycloheximide treatment of cells (McCusker et al. 1990 , McCusker & Clemmons 1997 , and even to acid treatment (unpublished data), but added pure IGFBP-3 only binds loosely to cells and can be readily washed off (unpublished data). Ideally, to understand how IGFBP activity is modulated, the IGFBP secreted by a given cell should be studied.
We have recently reported that Zn 2+ retains IGFBP-3 and IGFBP-5 on cell surfaces in a low affinity state that can then bind the IGFs, but does not retain IGFBP-2 or IGFBP-4 on cell surfaces (McCusker & Clemmons 1997) . In addition to IGF location, an additional level of regulation must control IGF activity; i.e. a mechanism(s) must exist to release IGF from IGFBPs to permit IGF-1R activation. Release may involve proteolysis of the soluble IGFBPs found in serum and other extracellular fluids (Camacho-Hubner et al. 1992 , Conover & Kiefer 1993 , Fowlkes et al. 1994 , Kanzaki et al. 1994 , Kajimoto et al. 1995 . Proteolysis of IGFBP-3 lowers ligand affinity (Baxter & Skriver 1993 , Lamson et al. 1993 , Blat et al. 1994 , thus releasing IGFs. IGFBP-4 is proteolytically cleaved in extracellular fluids and this action has been proposed as a sensitive mechanism controlling the amount of free IGF in fluids. In contrast to soluble IGFBPs, cell-associated IGFBPs appear to be resistant to proteolysis (Jones et al. 1993) . Depressed binding of IGFs to cellassociated IGFBPs involves Zn 2+ -induced decreases in IGFBP-3 and IGFBP-5 affinity (Sackett & McCusker 1998a,b I-IGF binding to soluble IGFBPs and cell surfaces using cells grown in zinc-deficient conditions with and without Zn 2+ supplementation during the binding assay. Our previous data had outlined a hierarchy for the affinity of IGF for IGFBP-3, IGFBP-5 and the IGF-1R (McCusker et al. 1990 , 1998 , McCusker & Clemmons 1997 , Sackett & McCusker 1998a . Those data defined step-wise changes in ligand affinity (K a I-IGF binding to the soluble IGFBP-4 secreted by differentiation-deficient L6 (L6.dd) myoblasts although it did depress the affinity of soluble IGFBP-5. The new data from this manuscript adds to and refines the affinity hierarchy (Table 1) in particular for IGFBP-4 and IGF receptors and provides substantial evidence that Zn 2+ acts to modulate IGF distribution, dependent on the IGFBP secreted by the cell being studied, in this case skeletal muscle myoblasts.
Materials and Methods

Cell culture
P 2 A 2a -LISN mouse myoblasts were a generous gift from Dr M Kaleko (Quinn et al. 1993) . These cells constitutively over-express the human IGF-1R and were sub-cultured once a week as previously described (McCusker et al. 1990 . L6 rat myoblasts were purchased from the American Type Culture Collections (Rockville, MD, USA). Differentiation-deficient L6 cells (L6.dd) were generated as previously described (McCusker & Clemmons 1988) . L6.dd cells were subcultured weekly as previously described (McCusker & Clemmons 1988 , McCusker et al. 1990 ). Cells were grown in Dulbecco's minimum essential medium (DMEM; Gibco BRL, Grand Island, NY, USA) plus 10% fetal bovine serum (FBS) (JRH, Lenexa, KS, USA), 5·6 mM additional glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin (Sigma Chemical Co., St Louis, MO, USA). DMEM does not contain Zn 2+ . Under these conditions, cells were maintained in approximately 10% circulating Zn 2+ levels, i.e. that supplied from the FBS (zinc-deficient conditions). ZnCl 2 (Zn 2+ ) was purchased from Sigma. Sodium (Na)-insulin was purchased from Gibco BRL (Gaithersburg, MD, USA). Zn 2+ was dissolved in water and did not change the pH of the assay buffer when added at up to 200 µM. Other chemicals were purchased from Sigma unless indicated otherwise.
Cell binding assay
Confluent cultures (7-9 days on 2 cm 2 wells) were rinsed twice with PBS then incubated with Hank's balanced salt solution (HBSS) for 3 h at 4-7 C to allow dissociation of any cell-associated IGFs. Cells were then rinsed twice with PBS and once with HBSS (Gibco). Binding assays were performed at 4-7 C with Eagle's minimal essential medium (EMEM; Gibco), without sodium bicarbonate, supplemented with 20 mM HEPES and 1% BSA, final pH 7·4. EMEM does not contain Zn
2+
. When Zn 2+ was added during the binding assay, control wells contained an equal volume (5 µl) of water. Radiolabeled IGF-I, R 3 -IGF-I and IGF-II (70-90 000 c.p.m., ]0·6 ng/ml) were added with varying doses of unlabeled Na-insulin, IGF-I, R 3 -IGF-I or IGF-II (500 ng/ml IGF for non-specific binding (NSB)) to a final volume of 250 µl. After 3 h, the assay buffer above the cells (AB) was either collected into 12 75 mm polystyrene tubes or discarded and the cells were rinsed with PBS. NaOH (0·3 M) was added to solubilize the cells for transfer to 12 75 mm tubes to quantify cell surface bound 125 I-IGF. P 2 A 2a -LISN mouse or L6.dd rat myoblast conditioned medium (DMEM), containing secreted IGFBPs, was added to some wells as part of the final 250 µl with an equal volume of non-conditioned DMEM as controls. This enables simultaneous quantification of 125 I-IGF binding to soluble IGFBPs and the cell surface, and interactions between the two binding sites. To measure 125 I-IGF binding to soluble IGFBPs, the assay buffer was collected into 12 75 mm tubes; bound and free 125 I-IGF were separated by polyethylene glycol (PEG)-8000 precipitation of bound ligand (McCusker et al. 1990) .
Conditioned media binding assay
Twenty-four-hour serum-free conditioned media samples were prepared by incubating confluent cultures with DMEM plus antibiotics and 100 µg/ml BSA-linoleic acid. IGF binding to medium aliquots was performed as previously described (McCusker & Clemmons 1988) . In brief, aliquots of conditioned media were incubated for 2-3 h at room temperature with 125 I-IGFs. Bound and free IGF were separated by precipitation with PEG-8000.
Dose dependence
Dose-response relationships were determined in the presence of 0, 5, 10, 20, 30, 50, 100 and 200 µM Zn 2+ . Data were curve-fitted and ED 50 was determined using SigmaPlot Table Curve 2D program (Jandel Scientific Software, San Rafael, CA, USA).
Ligand blot analysis and immunoblot analysis
Conditioned media samples (23 µl) were electrophoresed through polyacrylamide gels and transferred to Immobilon-P (Bio-Rad Laboratories, Hercules, CA, USA) membranes (McCusker & Clemmons 1988) . Western blots were prepared in which the same collection of media was loaded on each lane. Blots were cut into strips. The Western blots strips were incubated overnight with the indicated radiolabeled ligand before being exposed to PhosphoImager Screens (Molecular Dynamics, Sunnyvale, CA, USA) for 7 days. Additional sections of the Western blot were incubated with a 1:1000 dilution of antisera to specific IGFBPs (UBI, Lake Placid, NY, USA). The blot was then incubated with a secondary antibody linked to alkaline phosphatase. Immunoreactive bands were visualized using the Protoblot (Promega, Madison, WI, USA) reagents (McCusker et al. 1989b) .
Affinity labeling
Affinity labeling of cell surface binding sites was performed with disuccinimidyl suberate (Pierce, Rockford, IL, USA) as described (McCusker et al. 1990) . Cells solubilized directly in Laemmli buffer containing 6% -mercaptoethanol were electrophoresed through 5-18% gradient SDS-polyacrylamide gels. Dried gels were exposed to PhosphoImager Screens for 30 days.
Iodine labeling
IGF-I, IGF-II (Bachem, Torrance, CA, USA), R 3 -IGF-I (Gro-Pep, Adelaide, Australia) and Na-insulin were iodinated with chloramine-T (Sackett & McCusker 1998a) . Specific activities ranged between 180 and 300 µCi/µg. R 3 -IGF-I binds poorly to IGFBPs but with normal affinity to the IGF-1R , Sackett & McCusker 1998a .
Data analysis
Competitive binding assays were analyzed by Scatchard analysis to quantify affinity constants (K a ) and number of binding sites (R o ) (Scatchard 1949 
Results
Secreted IGFBPs
P 2 A 2a -LISN cell conditioned media were subjected to ligand blot and immunoblot analysis to identify secreted IGFBPs. Ligand blots revealed bands at 31 000 and 20 000 M r (Fig. 1) . Both IGFBP-5 bands preferred 125 I-IGF-II over 125 I-IGF-I. Both ligand blot bands reacted with IGFBP-5 antiserum, as did additional bands at 35-36 000 M r that did not bind the 125 I-IGFs. There was no immunoreactivity with antisera to IGFBP-1, -2, -3 or -4. L6.dd cells secrete primarily IGFBP-4 at 24 000 M r and traces of IGFBP-5 at 31 000 M r . The identity of both IGFBPs was confirmed by immunoblot analysis (Fig. 1 ). There was no immunoreactivity with antisera to IGFBP-1, -2 or -3. L6.dd cell-derived IGFBP-4 bound similar amounts of I-IGF-I binding with similar potency; however, IGF-I displaced only 18% of the 125 I-IGF-II at 41 ng/ml and 66% at 500 ng/ml compared with IGF-II displacement at the same doses. The competition pattern was similar in the presence of Zn 2+ ( Fig. 2 
Specificity of IGF binding to soluble IGFBPs
bottom B-I and B-II). IGF-I and IGF-II competed equally well for
125 I-IGF-I binding but IGF-I displaced only 11% of the 125 I-IGF-II at 41 ng/ml but 68% at 500 ng/ml compared with IGF-II Figure 1 Ligand and immunoblot analysis of the IGFBPs secreted by P 2 A 2a -LISN and L6.dd cells. Conditioned media were collected and electrophoresed through discontinuous SDS-polyacrylamide gels. After transfer to Immobilon-P, the Western blots were cut into strips and incubated with the indicated 125 I-peptide or antiserum. The ligand blots were taken from representative single Western blots cut into strips thus avoiding variation in gel electrophoresis or transfer efficiency. Mobilities (M r ) of reactive bands are indicated. Strips were also incubated with antisera to IGFBP-1, -2, -3 and -4 without reactivity for P 2 A 2a -LISN conditioned media and with antisera to IGFBP-1, -2, and -3 without reactivity for L6.dd conditioned media (not shown).
displacement at the same doses. Most importantly, Zn 2+ did not lower specific binding (B i ) of either ligand.
Effect of Zn 2+ on IGF binding to secreted soluble IGFBPs
Previous work quantifying IGFBPs secreted by muscle cells was performed at pH=6·0 (McCusker & Clemmons 1988 , 1998 , McCusker et al. 1989b I-IGF-II to secreted soluble IGFBP-5 in P 2 A 2a -LISN cell conditioned media (top) and secreted soluble IGFBPs in L6.dd cell conditioned media (bottom). Conditioned media aliquots were incubated with assay buffer at the indicated pH with the indicated radiolabeled peptide in the absence or presence of Zn 2+ (200 M). Specific binding was quantified as the difference between binding in the absence (B o ) and presence (NSB) of 500 ng/ml of the homologous unlabeled peptide. Data represent means S.E.M. of 11 or 9 determinations at pH=6 and 6 determinations at pH=7·4 for P 2 A 2a -LISN media and 12 or 10 determinations at pH=6 and 6 or 5 determinations at pH=7·4 for L6.dd media. Three separate conditioned media aliquots were used (some assayed several times) and assays were conducted using three different iodinations of each tracer. concave-down plots and the calculation of binding constants for both high and low affinity sites (example for 125 I-IGF-II, pH 7·4 shown in Fig. 4, top) . In contrast, Zn 2+ flattened and straightened the Scatchard plots and in most cases only a single-affinity binding site was identified (Fig. 4, bottom) . After repeated analysis, again IGFBP-5 bound more 125 I-IGF-II than 125 I-IGF-I ( -IGF-I does not recognize the IGFBP-5 secreted by these cells (Fig. 1 top) this band is as yet unidentified. All binding was specific as indicated by the decrease in band intensities in the presence of unlabeled peptides (Fig. 5 top) . There was no evidence of the insulin receptor ( L6.dd cell surface binding sites were also affinity labeled (Fig. 5 bottom) (Fig. 6 bottom) with offsetting effects on c.p.m. bound and overall binding affinity, although the slight non-significant increase in affinity probably represents an increase in IGF-1R binding avidity. Thus, the specificity data in Fig. 6B and the Scatchard analysis data in Table 3 (L6.dd data) indicate that Zn 2+ decreases the affinity by Specificity of IGF binding to P 2 A 2a -LISN and L6.dd cell surfaces in the absence (control) or presence of Zn 2+ . P 2 A 2a -LISN (top) and L6.dd (bottom) were incubated with the indicated radiolabeled ligand for 3 h at 5 C. The ability of IGF-I (500 ng/ml), IGF-II (500 ng/ml), R 3 -IGF-I (500 ng/ml) and Na-insulin (100 g/ml) to compete for 
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well. An equal volume of non-conditioned media served as the control.
I-IGF-I binding
In the absence of IGFBP-5, there was no specific IGFcompetable binding of 125 I-IGF-I in the assay buffer above P 2 A 2a -LISN cells (Fig. 7 A-I The ability of Na-insulin to displace binding to the cell surface was assessed as an additional indication of IGF-I binding to the IGF-1R. Insulin displaced 59% as much of the 125 I-IGF-I as did unlabeled IGF-I (Fig. 7 B-I vs C-I ). In the absence of IGFBP-5, Zn 2+ increased insulincompetable binding (Fig. 7 C-I ). The presence of P 2 A 2a -LISN conditioned media containing IGFBP-5 depressed Na-insulin competable -IGF-I in the assay buffer above P 2 A 2a -LISN cells (Fig. 7 A-R) .
In the absence of IGFBPs, the P 2 A 2a -LISN cell surfaces specifically bound (R   3   -IGF-I competable) 125 I-R 3 -IGF-I (Fig. 7 B-R (Fig. 7 B-R vs C-R) . In the absence of IGFBP-5, Zn 2+ increased insulin-competable binding (Fig. 7 C-R 
I-IGF-II binding
In the absence of IGFBP-5, there was no specific (IGF-II competable) binding of 125 I-IGF-II in the assay buffer above P 2 A 2a -LISN cells (Fig. 7 A-II) . The presence of P 2 A 2a -LISN conditioned media containing IGFBP-5 resulted in specific binding of 125 I-IGF-II in the assay buffer. Zn 2+ decreased the binding activity in the assay buffer. In the absence of IGFBPs, the P 2 A 2a -LISN cell surfaces specifically bound (IGF-II competitive) 125 I-IGF-II (Fig. 7 B-II (Fig. 7 B-II vs C-II) . In the absence of IGFBP-5, Zn 2+ increased insulin-competable binding (Fig. 7 C-II) . The presence of P 2 A 2a -LISN conditioned media containing IGFBP-5 resulted in a decrease in the .dd cell surfaces. Cells were incubated with the indicated radiolabeled peptide in the absence (control) or presence of Zn 2+ . Binding was assessed without ( ) or with (+) 50 l of P 2 A 2a -LISN conditioned medium or 75 l of L6.dd conditioned medium. Binding is expressed as the difference in binding in the absence and presence of unlabeled peptide (IGF 500 ng/ml or Na-insulin at 100 g/ml). Binding to the cell surface and to the IGFBPs in the assay buffer was quantified as described in Materials and Methods. Na-insulin did not compete for binding to IGFBPs (data not shown). Data represent means S.D. P 2 A 2a -LISN data: n=5 for IGF-I and IGF-II and n=4 for R 3 -IGF-I and insulin data. L6.dd data: n=5 for IGF-I and IGF-II and n=4 for R 3 -IGF-I and insulin data. *P,0·05 for the effect of Zn (Baxter 1994 , McCusker 1998 (Ernst et al. 1992 , McCusker & Clemmons 1994 , Ewton & Florini 1995 , P 2 A 2a -LISN cells appear to secrete only one form of IGFBP, IGFBP-5, and unlike the IGFBP-5 produced by fibroblasts and glioblastoma cells (McCusker et al. 1990 , McCusker & Clemmons 1997 , Sackett & McCusker 1998a the IGFBP-5 produced by these cells does not reside on the cell surface in any substantial quantity. Even in the presence of Zn 2+ , the IGFBP-5 produced by these cells remains soluble as evidenced by the unchanging percentage of insulin-competable IGF that binds to P 2 A 2a -LISN cell surfaces and the lack of IGFBP-5 adherence to the cells in the presence of Zn 2+ by affinity crosslinking (not shown). In our previous work, Zn 2+ depressed the affinity of IGF-I and IGF-II binding to cell-associated IGFBP-3 and IGFBP-5 (Sackett & McCusker 1998a,b) . In those studies, cultured cells always produced more than one form of IGFBP. In the current work, P 2 A 2a -LISN cells make only IGFBP-5. Therefore, the inhibitory effect of Zn 2+ on ligand affinity is confirmed when only IGFBP-5 is present. In addition, current knowledge is expanded to show that ligand affinity is depressed for soluble IGFBP-5 agreeing with our published work with cellassociated IGFBP-3 and IGFBP-5 (Sackett & McCusker 1998a,b) .
Similar to our work with cell-associated IGFBP-5 and IGFBP-3 (McCusker et al. 1990 , Sackett & McCusker 1998a , the Scatchard plots for IGF-I and IGF-II binding to soluble IGFBP-5 were curvilinear, concave-down. The reason for the curvilinear plots is unknown, thus affinity constants were calculated assuming both Pre-Existent and Ligand-Induced models. Independent of the mode of calculation, zinc markedly depressed or eliminated the high-affinity binding state and depressed the strength of the low-affinity binding state. This finding was like the effect of Zn 2+ on the affinity of cell-associated IGFBP-5, whereby both the low and high affinity sites were affected, although the low affinity site was less affected than the high affinity site (McCusker et al. 1990 , Sackett & McCusker 1998a .
Of note is the effect of pH on IGFBP-5. The soluble IGFBP-5 produced by P 2 A 2a -LISN cells bound more 125 I-IGF-I and 125 I-IGF-II at pH 6·0 than at pH 7·4 (Table 2) . However, binding affinities were much higher at pH 7·4 than at pH 6·0. The difference in binding was due to the detection of two-to fourfold more binding sites at pH 6·0 than at pH 7·4. This effect is probably not a result of low pH inducting additional binding sites but rather an increase in precipitation of the IGF-IGFBP complex, i.e. the efficiency of detection. Caution must be employed when interpreting the results of other published work when comparing binding at varying pH if only the amount (c.p.m.) bound is presented; affinity and number of binding sites must be calculated to properly interpret pH effects. In spite of this assay variable, the findings clearly indicate that IGFBP-5 affinity is depressed at pH 6·0 compared with the normal extracellular pH of 7·4. Independent of pH, the affinity of P 2 A 2a -LISN-derived soluble IGFBP-5 for either IGF-I or IGF-II is considerably higher than the IGF-1R of the same cells at pH 7·4 (Table  2 compared with Table 3 ). Only in the presence of Zn 2+ or with a change in pH does the affinity of soluble IGFBP-5 begin to approach that of the IGF-1R. This finding is analogous to cell-associated IGFBPs wherein the affinity of cell-associated IGFBP is depressed by the presence of Zn 2+ (McCusker et al. 1990 , McCusker & Clemmons 1997 and only then can binding actually favor the IGF-1R versus cell-associated IGFBPs.
Despite the relatively high affinity of Zn 2+ /IGFBP-5 versus that of the IGF-1R, Zn 2+ did partition IGFs away from soluble IGFBPs. By reducing the strength of the high affinity site, Zn 2+ reduced ligand binding to soluble IGFBP-5 and in doing so enabled the ligand, either IGF-I or IGF-II, to bind to the cell surface IGF-1R. This effect was present because Zn 2+ did not decrease, but increased, the affinity of the IGF-1R. The effect of Zn 2+ on IGF-1R affinity is similar to our previous work with these cells .
L6 cells, unlike several other muscle cell lines (Tollefsen et al. 1989 , Ernst et al. 1992 , McCusker & Clemmons 1994 , Ewton & Florini 1995 , secrete primarily IGFBP-4 under control conditions (McCusker et al. 1989a ,b, Li et al. 1996 , McCusker & Clemmons 1998 -3 and IGFBP-5 (McCusker et al. 1990 , McCusker & Clemmons 1997 , the IGFBP-4 secreted by L6 cells has only a single affinity binding site. However, the effect of pH on L6 cell IGFBP-4 ligand binding may be of physiological importance. IGFBP-4 bound almost twice as much of either IGF-I or IGF-II at pH 6·0 than at pH 7·4. This difference in binding was a result of a doubling in ligand affinity at pH 6·0 compared with pH 7·4. This pH preference is unlike that of the soluble IGFBP-5. This indicates that the IGF-IGFBP-4 complex would persist when exposed to the low pH of both the early and late endosomes within cells (Clague 1998), whereas IGFBP-5 affinity drops drastically with lower pH and thus the IGF-IGFBP-5 complex would tend to dissociate in early and late endosomes. The preservation of the IGF-IGFBP-4 complex over a wide yet physiological pH range may also ensure inactivation of IGFBP-4 by IGF-dependent proteases (Claussen et al. 1997 , RemacleBonnet et al. 1997 , Byun et al. 2001 , Overgaard et al. 2001 . At pH 7·4, the affinity of L6 cell-derived soluble IGFBP-4 for either IGF-I or IGF-II is three-to fourfold higher than the IGF-1R of the same cells in both the presence and absence of Zn 2+ (Table 2 versus Table 3 ). Thus, Zn 2+ is unable to depress IGFBP-4 affinity to favor IGF-1R association as it does for soluble IGFBP-5. Clearly, release of the IGF bound to L6 cell-derived IGFBP-4 must occur via another mechanism, most probably proteolysis (Baxter 2000) . In the light of these findings, IGFBP-4 depressed binding of IGF-I and IGF-II to L6.dd cell surface IGF-1Rs. Zn 2+ was unable to reverse this inhibitory effect as it did for P 2 A 2a -LISN cells that secrete IGFBP-5. Zn 2+ did, however, increase the affinity of the IGF-1R on L6 cells similar to our work with P 2 A 2a -LISN cells.
In addition to the IGF-1R on L6 cells, which bound both IGF-I and R 3 -IGF-I with similar affinity, there were additional numerous binding sites obvious only when IGF-II was used as the binding ligand. The K a of this already low affinity site was depressed 10% by Zn 2+ . We have tentatively identified this site as the IGF-2R based on (1) its preference for IGF-II, whereas the IGF-1R prefers IGF-I as does IGFBP-4; (2) Binding site number, R o , the binding moiety is not the IGF-1R given the similar number of sites for IGF-I and R 3 -IGF-I binding but the much greater number of binding sites for IGF-II, (3) location on the cell surface, (4) the absence of such a low affinity site on cells with IGFBPs or IGF-1R as their most numerous cell surface binding site , Sackett & McCusker 1998a . L6 cells do have IGF-2Rs (Ballard et al. 1986 , Ewton et al. 1987 , Kiess et al. 1987 , Clairmont & Czech 1991 I-IGF-II affinity labels exclusively the IGF-2R on L6 cells, (Ballard et al. 1986 , Kiess et al. 1987 despite 125 I-IGF-I clearly labeling the IGF-1R. One study indicates a preference for 125 I-IGF-II labeling the IGF-2R over the IGF-1R (Ballard et al. 1988) and one study found similar labeling of both the IGF-1R and IGF-2R with 125 I-IGF-II using L6 cells (Ewton et al. 1987) . Our finding of 125 I-IGF-II affinity labeling of the IGF-1R but not the IGF-2R adds another twist to this complex story (all studies used disuccinimidyl substrate as the affinity labeling cross-linker). Until other studies confirm a Zn 2+ effect on purified IGF-2R, the new data in this manuscript indicate that Zn 2+ depresses the affinity of the IGF-2R. By doing so, Zn 2+ should partition the IGFs, especially IGF-II, away from the IGF-2R and onto the IGF-1R; indeed there was an increase in R 3 -IGF-I and insulin-competable 125 I-IGF-II binding in the presence of Zn 2+ despite a decrease in overall 125 I-IGF-II binding (Fig. 6 bottom) . We believe that the 10% decrease in IGF-2R affinity is an underestimate of the true effect of Zn
2+
.
125 I-IGF-II binds to both the IGF-2R and IGF-1R and IGF-1R affinity for 125 I-IGF-II is increased by Zn 2+ (see P 2 A 2a -LISN data). Thus, the true decrease in 125 I-IGF-II binding to the IGF-2R is partially hidden by (Oka et al. 1985 , Nielsen et al. 1991 and increase IGF-1R binding. Thus, dependent on the form of IGFBP secreted by cells, Zn 2+ may or may not redistribute IGF away from soluble-inhibitory IGFBPs to the IGF-1R. The structure of the IGF-1R is based on IGF-1R sequence information, limited 3-D structure of the IGF-1R (Garrett et al. 1998) and supplemental 3-D information of the insulin receptor (Ottensmeyer et al. 2000) . The structure of IGFBP-5 is based on the concept that IGFBPs have three distinct domains, the N-domain and C-domain being directly involved in ligand binding and the variable L-domain linking the two (Hwa et al. 1999) . Disulfide bond alignments have not been completely defined for any IGFBP but information from several IGFBPs were combined to show probable pairings for IGFBP-1 through -5 (Brinkman et al. 1991 , Tressel et al. 1991 , Hashimoto et al. 1997 , Forbes et al. 1998 , Kalus et al. 1998 , Neumann & Bach 1999 , Chelius et al. 2001 . CR, cysteine-rich domain; L1, L2, large domains 1 and 2; Fn, fibronectin type III-like domain.
